The Lancet Oncology
Fecha de publicación: 29 january 2019
Autores: Eitan Amir
Background: Compared with definitive endpoints such as overall survival, the use of intermediate endpoints such as disease-free survival improves the efficiency of trial design, resulting in studies requiring smaller sample sizes and shorter follow-up. In oncology, the validation of intermediate endpoints as adequate surrogates of definitive outcomes is challenging.